Belle et al. [34] evaluated the efficacy of the HBV vaccine between IBD patients and healthy controls and investigated the impact of immunosuppressive therapy on vaccine response in IBD patients between the three IBD treatment approaches (anti-TNF, thiopurine, combination therapy, and no therapy); among the 164 participants, the median titers of anti-HBs did not differ between the sub-groups, at 246.25 ± 330.88, 275.93 ± 369.99, 273.54 ± 357.58, and 306.91 ± 385.49, respectively. The gene discussed is TNF; the disease is inflammatory bowel disease.